Therapie. 2017 Feb 17. pii: S0040-5957(17)30035-5. doi: 10.1016/j.therap.2016.12.011. [Epub ahead of print]
[Article in French]
- 1
- Département de médecine générale, Aix-Marseille université, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France.
- 2
- Département de médecine générale, Aix-Marseille université, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France. Electronic address: ludovic.casanova@inserm.fr.
Abstract
AIM:
In
vitro Influenzinum induce a cellular change. We present the results of
the first study examining the effectiveness of Influenzinum against
influenza-like illnesses.
METHOD:
Retrospective
cohort study during winter 2014-2015. After influenza epidemic, a
self-assessment questionnaire was offered to patients presenting for a
consultation. The primary endpoint was the declaration of an
influenza-like illness. The exposed patients (treated by Influenzinum)
were matched to two non-exposed patients (untreated) with a propensity
score. A conditional logistic model expressed influenza-like illness
risk reduction provided by the Influenzinum.
RESULTS:
The
cohort included 3514 patients recruited from 46 general practitioners.
After matching, the treated group (n=2041) and the untreated group
(n=482) did not differ on variables collected. Influenzinum preventive
therapy does not significantly alter the likelihood of influenza-like
illness (adjusted odds ratio=0,91 [0,62 to 1,35], p=0,64).
CONCLUSION:
Influenzinum preventive therapy did not appear effective in preventing influenza-like illness.
Copyright © 2017 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.
KEYWORDS:
Active immunization; Ambulatory care; Grippe humaine; Homeopathy; Homéopathie; Human influenza; Influenzinum; Médecine ambulatoire; Propensity score; Score de propension; Vaccination
